Clinical trials: Central Nervous System Lesion
Alzheimer Disease
A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects
Study of the Safety, tolerability and pharmacokinetics with single dose of donepezil patch in healthy male subjects.
- Trial name
- NCT01860625
- Testing
- Donepezil patch
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Icure Pharmaceutical Inc.
IDIOPATHIC PARKINSON'S DISEASE
Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients
The primary objective is to demonstrate that the Rotigotine transdermal patch is efficacious in Chinese subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- NCT01646268
- Testing
- Rotigotine
- Where
- 24 sites in China
- Volunteers
- 249 people
- Sponsor
- UCB Pharma
Acute Myocardial Infarction, Restenoses, Coronary
Abbott Vascular Medical Device Registry
The AV-MDR is a prospective, non-randomized, open-label, multi-center registry. The purpose of the AV-MDR study is to proactively collect and evaluate clinical data on the usage of the devices in scope within their intended use…
- Conditions
- Acute Myocardial Infarction, Restenoses, Coronary, Coronary Artery Lesions, Venous Embolism
- Trial name
- AV-MDR (NCT04573660)
- Testing
- Coronary and peripheral stents, Pacing catheters, Vascular plugs
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 3,784 people
- Sponsor
- Abbott Medical Devices
Alzheimer Disease
A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.
Study of the Safety, tolerability and pharmacokinetics with multiple doses of donepezil patch in healthy male subjects
- Trial name
- NCT02178124
- Testing
- Donepezil
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Icure Pharmaceutical Inc.
Vascular Diseases, Peripheral Arterial Disease
Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery
The objective of this post-market clinical follow-up study is to evaluate the clinical outcomes of patients receiving PhotoFix as a patch within a vascular repair or reconstruction procedure.
- Conditions
- Vascular Diseases, Peripheral Arterial Disease, Hemodialysis Access Failure (Disorder), Carotid Artery Diseases
- Trial name
- PHOTO-V (NCT03669042)
- Testing
- PhotoFix
- Where
- 9 sites in United States
- Volunteers
- 94 people
- Sponsor
- Artivion Inc.
Smokers
Nicotine Patch Safety Study
The purpose of this study is to evaluate the safety profile of a repeated application of a new transdermal patch compared to a reference product during 3 weeks, in a large population.
- Trial name
- NCT01655082
- Testing
- V0116 transdermal patch, Nicotine transdermal patch
- Where
- 4 sites in France
- Volunteers
- 160 people
- Sponsor
- Pierre Fabre Medicament
Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
First-in-Human Study Using the SiroMax™ Sirolimus-Coated Balloon Catheter as a Percutaneous Transluminal Coronary Angioplasty (PTCA) Balloon Catheter to Treat Subjects Who Have Coronary Artery Disease (CAD) Involving In-Stent Restenosis (ISR) or an Unstented Lesion in a Small Coronary Vessel (DNSV).
The goal of this clinical trial is to learn if the SiroMax™ drug-coated balloon catheter is safe and works to treat stenotic coronary lesions in adults.
- Conditions
- Coronary Artery Disease, Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), In-Stent Restenosis or De Novo Coronary Artery Lesions, In-Stent Stenosis (Restenosis) of Coronary Artery Stent
- Trial name
- SMART-I (NCT07811024)
- Testing
- Sirolimus-coated balloon catheter
- Where
- 2 sites in Uzbekistan
- Volunteers
- 60 people
- Sponsor
- Tonic Medical, Inc.
Alzheimer's Disease
Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44
The core study assessed the efficacy of a higher dose of rivastigmine 13.3 mg/24 h transdermally (15 cm^2 patch) compared to a lower dose of the rivastigmine 4.6 mg/24 h transdermally (5 cm^2 patch) in patients with Severe…
- Trial name
- ACTION (NCT00948766)
- Testing
- Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2)
- Where
- 95 sites in United States, Puerto Rico
- Volunteers
- 716 people
- Sponsor
- Novartis
Sleep Apnea, Obstructives, Sleep Apnea Central
Development of a Torso Patch Sensor (C-TraQ) as a Companion Device to a Fingertip Sensor (TipTraQ) for Direct Monitoring of Respiratory Effort
The existing PranaQ system utilizes a fingertip sensor that captures PPG(Photoplethysmography) and accelerometer data, and its clinical validation is well-established.
- Trial name
- NCT07744854
- Where
- Taiwan
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- PranaQ Pte. Ltd.
Suspected Arrhythmia, Palpitations
This Exploratory Medical Device Study Evaluated the Arrhythmia Diagnostic Yield of MEMO Patch V2, a Wearable Patch-type Electrocardiographic Monitor, in Adults With Suspected Arrhythmia Who Presented With Symptoms Such as Palpitations or Dizziness, or Who Had Cryptogenic Ischemic Stroke or Transient
This exploratory medical device study evaluated the arrhythmia diagnostic yield of MEMO Patch V2, a wearable patch-type electrocardiographic monitor, in adults with suspected arrhythmia who presented with symptoms such as…
- Conditions
- Suspected Arrhythmia, Palpitations, Dizziness, Cryptogenic Ischemic Stroke
- Trial name
- NCT07722026
- Testing
- MEMO Patch V2, 24-Hour Holter Monitor
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- HUINNO Co., Ltd
Bone Metastases
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid (Zometa®) in the treatment of bone metastases (lytic bone lesions from multiple myeloma) in subjects with advanced cancer and multiple…
- Trial name
- NCT00330759
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 1,779 people
- Sponsor
- Amgen
Alzheimer's Disease
Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease
This study used two doses of rivastigmine transdermal patch (5 cm^2, 10 cm^2) to establish the feasibility of 2 switch schedules (with transdermal patch one-step dose titration or without dose titration) from rivastigmine…
- Trial name
- KAPA (NCT00549601)
- Testing
- Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day), Rivastigmine patch (9.5 mg/day), Rivastigmine capsules (6 mg to 12 mg/day)
- Where
- Spain
- Volunteers
- 142 people
- Sponsor
- Novartis
Intracranial Atherosclerosis
An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis
The IRISS study is designed to collect clinical and angiographic outcomes data when stenting intracranial atherosclerotic lesions using the Wingspan™ Stent System with Gateway™ PTA Balloon Catheter in routine clinical practice.
- Trial name
- IRISS (NCT00929383)
- Testing
- Wingspan Stent System with Gateway PTA Balloon Catheter
- Where
- 19 sites in France, Germany
- Volunteers
- 82 people
- Sponsor
- Stryker Neurovascular
Parkinson Disease
A Study to Assess Pharmacokinetic Profiles of LY03003 and Neupro
Phase 1, single center study to assess pharmacokinetic profiles of rotigotine after single dose of LY03003 and daily patch application of Neupro in Healthy Volunteers
- Trial name
- NCT03733561
- Testing
- LY03003, Neupro 4Mg/24Hr Transdermal Patch
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Small/Large Bowel
PillCam SB3 Capsule- Feasibility Study
Study hypothesis: PillCam SB3 is a new capsule designed to provide an improved image quality, and improved SB and duodenum tissue coverage due to Adaptive Frame Rate (AFR) of 2-6 fps, which will create more images for evaluation…
- Trial name
- NCT01433042
- Testing
- capsule endoscopy
- Where
- 4 sites in Israel, Romania and 2 more
- Volunteers
- 225 people
- Sponsor
- Medtronic - MITG
Alzheimer's Disease, Dementia, Alzheimer Type
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
- Trial name
- NCT00099242
- Testing
- rivastigmine transdermal patch
- Where
- 75 sites in United States, Chile and 19 more
- Volunteers
- 1,040 people
- Sponsor
- Novartis Pharmaceuticals
CNS Lesion, Blood Brain Barrier Defect
Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
This trial aimed to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
- Trial name
- PICTURE (NCT03996447)
- Testing
- gadopiclenol, Gadobutrol 1Mmol/mL Solution for Injection Vial
- Where
- 33 sites in United States, Belgium and 9 more
- Volunteers
- 260 people
- Sponsor
- Guerbet
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months
This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine…
- Trial name
- NP101-009 (NCT00806546)
- Testing
- NP101
- Where
- 31 sites in United States
- Volunteers
- 514 people
- Sponsor
- NuPathe Inc.
Idiopathic Parkinson Disease
Adhesion and Safety of Rotigexole Compared to Neupro®
A non-inferiority open-labelled crossover randomized controlled trial, of two arms, to investigate the adhesiveness and safety of Rotigexole 8 mg/24 hours transdermal patch, manufactured by Eva pharma, Egypt, compared to the…
- Trial name
- START (NCT07015346)
- Testing
- Rotigexole 8 mg, Neupro ® 8 mg
- Volunteers
- 40 people
- Sponsor
- Eva Pharma
Alzheimer's Disease
A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
This study is designed to evaluate caregiver preference for Exelon® patch (target patch size 10 cm²) treatment in patients with Alzheimer's disease (MMSE 10-26) who were under cholinesterase inhibitor treatment and experienced…
- Trial name
- BETTER (NCT01047579)
- Testing
- Rivastigmine transdermal
- Where
- 5 sites in Israel
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals